噻托溴铵联合舒利迭治疗慢性阻塞性肺疾病的临床疗效观察

摘要

Objective :Analysis of tiotropium combined with Seretide in the treatment of chronic obstructive pulmonary disease (COPD) clinical curative effect .Methods :February 2012 to June 2014 in our hospital from chronic obstructive pulmonary disease patients of 486 cases ,were randomly divided into experimental group and control group ,226 cases of the control group ,with Seretide treatment ,the experimental group 260 cases ,with tiotropium bromide combined with Seretide in the treatment of type ,compared two groups of treatment effect .Results:There was no difference be-tween the two groups before treatment ,after treatment ,the blood gas analysis of experimental group was significantly improved ,the difference was statistically significant .The experimental group using tiotropium combined with Seretide treatment can improve pulmonary ventilation function was significantly higher than the control group .The total effec-tive rate of the treatment group was 96 .15% ,which was significantly higher than that of the control group (85 .40% ) , the difference was statistically significant (P<0 .05) .Conclusion:Using tiotropium bromide combined with Seretide in the treatment of chronic obstructive pulmonary disease (COPD) support the clinical effect is better than single seretide and can effectively improve the clinical symptoms in patients with sputum ,shortness of breath ,effectively improve the pulmonary function ,worthy of clinical use .%目的：分析噻托溴铵联合舒利迭治疗慢性阻塞性肺疾病（COPD）的临床疗效。方法：选择2012年2月-2014年6月我院收治的COPD患者486例，采用随机数字表法分为实验组和对照组，对照组226例采用舒利迭治疗方式，实验组260例采用国产噻托溴铵联合舒利迭治疗方式，比较两组治疗效果。结果：两组血气分析在治疗前无差异，治疗后实验组明显得到改善，差异具有统计学意义。实验组使用噻托溴铵联合舒利迭治疗肺通气功能改善情况明显高于对照组。实验组治疗总有效率为96．15％，明显高于对照组的85．40％，差异具有统计学意义（ P＜0.05）。结论：使用噻托溴铵联合舒利迭治疗COPD其临床效果优于单用舒利迭，还能够有效改善患者咳痰、气短等临床症状，有效改善肺功能，值得临床推广使用。